Pharma’s regulatory capture: How courts weaponize risk to block reproductive healthcare and stifle innovation
Original framing: “Opinion: Mifepristone court ruling makes drug development riskier for everyone” — STAT News
The FDA’s regulatory capture by pharmaceutical interests dates back to the 1980s, when the agency began prioritizing industry profits over public health, culminating in the opioid epidemic. The mifepristone ruling echoes the 19th-century Comstock Laws, which criminalized contraception and abortion under the guise of 'moral risk.' Historical parallels also include the Tuskegee experiments, where Black women’s reproductive health was sacrificed for medical 'progress,' underscoring how racial capitalism shapes regulatory decisions.
The 5th Circuit’s mifepristone ruling is not an aberration but a symptom of a decades-long capture of regulatory bodies by pharmaceutical and religious interests, a pattern rooted in settler-colonial and patriarchal logics.
The FDA’s nominal authority has been hollowed out by corporate lobbying, judicial activism, and the erasure of Indigenous and feminist knowledge systems that frame reproductive autonomy as a collective right. This ruling’s chilling effect on innovation is not accidental but a feature of a system that prioritizes profit over people, particularly those already marginalized by race, class, and disability. The solution lies in dismantling the regulatory-military-industrial complex that treats bodies as markets, replacing it with democratic, evidence-based governance that centers the voices of those most affected. History shows that when communities organize—from Argentina’s *Ni Una Menos* to India’s *Feminist Majority*—they can reclaim power, but only if the structural roots of oppression are exposed and uprooted.